Effects of Valsartan and Nebivolol treatment on blood pressure variability in hypertensive patients

Australasian Medical Journal

Volumn 1, Issue 4, 2010, Pages 248-252

  Negrea, Stefania ^a   Latea, Luminita ^a   Bolboacǎ, Sorana Daniela ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

ABPM; Blood pressure variability; Hypertension; Nebivolol; Valsartan

Indexed keywords

NEBIVOLOL; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; FEMALE; HEALTH CENTER; HEART PROTECTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NIGHT; OUTPATIENT; PROSPECTIVE STUDY; ROMANIA; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT;

EID: 77952766778     PISSN: None     EISSN: 18361935     Source Type: Journal    
DOI: 10.4066/AMJ.273     Document Type: Article

References (30)

1. Mancia G, De Backer G, Dominiczak A et al ESHESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. J Hypertens 2007 Sep;25(9):1751-1762
2. Parati G, Faini A, Valentini M. Blood pressure variability: its measurement and significance in hypertension.Curr hypertens Rep.2006; 8 (3):199-204
3. Kumar S, Venkata S Ram. Angiotensin Receptor Blockers: Current Status and Future Prospects. Indian Heart J 2007; 59(6): 443-453
4. Lindholm LH, Carlberg B, Samuelsson O. Should b blockers remain first choice in the treatment of primary hypertension? A metaanalysis.Lancet 2005; 366: 1545-1553
5. Conway J, Boon N, Davies C, Jones J, Sleight P. Neural and humoral mechanisms involved in blood pressure variability. J Hypertens 1984;2:203-208 (Pubitemid 14095784)
6. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002;113: 409-418 (Pubitemid 35230007)
7. Prasad A, Tupas-Habib T, Schenke WH et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349-2354 (Pubitemid 30329123)
8. Su KH, Tsai JY, Kou YR et al.Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signaling. Cardiovasc Res (2009) 82(3): 468-475
9. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, et al. SENIORS Investigators.Randomized trial to determine the effect of Nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-225 (Pubitemid 40222359)
10. Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallelgroup study to assess the efficacy and safety of Nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens. 2007;9(9):667-676
11. Mancia G, Di Rienzo M, Parati G. Ambulatory blood pressure monitoring in hypertension research and clinical practice. Hypertension 1993;21:510-524 (Pubitemid 23095166)
12. Mancia G, Parati G, Omboni S, Ulian L, Zanchetti A. Ambulatory blood pressure monitoring. Clin Exper Hypertens 1999;21:703-715
13. Mancia G, Parati G, Di Rienzo M, Zanchetti A. Blood pressure variability. In: Zanchetti A, Mancia G, eds. Handbook of hypertension, vol17:Pathophysiology of hypertension. Amsterdam: Elsevier Science 1997; 117-169
14. Sega R, Cesana G, Bombelli M et al. Seasonal variations in home and ambulatory blood pressure in the PAMELA population. J Hypertens 1998;16:1585-1592 (Pubitemid 28515484)
15. Grassi G, Turri C, Vailati S, Dell'Oro R, Mancia G. Muscle and skin sympathetic nerve traffic during the "white-coat" effect. Circulation 1999;100:222-225
16. Mancia G, Parati G, Pomidossi G, Casadei R, Di Rienzo M, Zanchetti A. Arterial baroreflexes and blood pressure and heart rate variabilities in humans. Hypertension 1986;8:147-153 (Pubitemid 16105223)
17. Cowley AW, Liard LF, Guyton AC. Role of the baroreceptor reflex in daily control of arterial blood pressure and other variables in dog. Circ Res 1973;32:564-576
18. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998;31:68-72 (Pubitemid 28124694)
19. Watson RDS. , Stallard TJ, Flinn RM, Littler WA: Factors determining arterial pressure and its variability in hypertensive man. Hypertension 1980;2:333-341
20. Floras JS, Hassan MO, Vann Jones J et al. Factors influencing blood pressure and heart rate variability in hypertensive humans. Hypertension 1988;11:273-281
21. Parati G, Frattola A, Di Rienzo M, Mancia G. Blood Presure Variability.Importance in Research and in Clinical Hypertension.Arq Bras Cardiol 1996;67:131-133
22. Ohkubo T, Imai Y, Tsuji I et al. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: The Ohasama Study. Hypertension 1998;32:255-259 (Pubitemid 28376481)
23. Rosendorff C, Black HR, Cannon CP, Gersh BJ, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761-2788. (Pubitemid 46842793)
24. World Health Organization-International Society of Hypertension Prevention of Cardiovascular Disease Guidelines for assessment and management of cardiovascular risk 2007. www.ishworld.com/documents/71665-71665-oms- intretiration.pdf
25. National Institute for Health and Clinical Excellence (NICE) and British Hypertension Society (BHS) Hypertension Guidelines 2006. Management of hypertension in adults in primary care www.nice.org.uk/CG034NICEguideline
26. Guide to management of hypertension 2008. Assessing and managing raised blood pressure in adults.http://www.heartfoundation.org.au/ SiteCollectionDocuments/A-Hypert-Guidelines2008-2009Update-FINAL.pdf
27. Oparil S, Silfani T, Walker J.Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals American Journal of Hypertension, Volume 18, Issue 2, Pages 287-294
28. Joint National Committee on Prevention, Detectioevaluation, and Treatment of High Blood Pressure. The seventh report of the Joint National Committee on Prevention,Detection, evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252 (Pubitemid 37553153)
29. Burnier M, Bullani R, Vogt B.Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?Current Hypertension Reviews, 2007, 3, 15-20
30. Verdecchia P, Angeli F, Gattobigio R. , Rapicetta C, Reboldi G. Impact of blood Pressure Variability on Cardiac and Cerebrovascular Complications in Hypertension. Am J Hypertens 2007;20;154-161 (Pubitemid 46150022)